JNJ Stock Forecast 2025-2026
Distance to JNJ Price Targets
JNJ Price Momentum
🤔 Considering J&J (JNJ)?
Join 5,000+ investors getting our exclusive market analysis every Monday & Thursday. Stay ahead of breakout opportunities.
Latest JNJ Stock Price Targets & Analyst Predictions
Based on our analysis of 28 Wall Street analysts, JNJ has a neutral consensus with a median price target of $166.37 (ranging from $150.00 to $190.00). The overall analyst rating is Buy (7.5/10). Currently trading at $162.81, the median forecast implies a 2.2% upside. This outlook is supported by 9 Buy, 13 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Alexandria Hammond at Wolfe Research, projecting a 16.7% upside. Conversely, the most conservative target is provided by Narumi Nakagiri at Daiwa Capital, suggesting a 7.9% downside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
JNJ Analyst Ratings
JNJ Price Target Range
Latest JNJ Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for JNJ.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Mar 12, 2025 | Guggenheim | Vamil Divan | Neutral | Reiterates | $0.00 |
| Mar 10, 2025 | Guggenheim | Vamil Divan | Neutral | Reiterates | $0.00 |
| Mar 5, 2025 | B of A Securities | Tim Anderson | Neutral | Maintains | $171.00 |
| Feb 19, 2025 | RBC Capital | Shagun Singh | Outperform | Reiterates | $181.00 |
| Feb 3, 2025 | Guggenheim | Vamil Divan | Neutral | Maintains | $166.00 |
| Jan 28, 2025 | Barclays | Matt Miksic | Equal-Weight | Maintains | $166.00 |
| Jan 23, 2025 | Wells Fargo | Larry Biegelsen | Equal-Weight | Maintains | $152.00 |
| Jan 23, 2025 | RBC Capital | Shagun Singh | Outperform | Reiterates | $181.00 |
| Jan 23, 2025 | Stifel | Rick Wise | Hold | Maintains | $155.00 |
| Jan 23, 2025 | B of A Securities | Tim Anderson | Neutral | Maintains | $159.00 |
| Jan 23, 2025 | Raymond James | Jayson Bedford | Outperform | Maintains | $165.00 |
| Jan 23, 2025 | Morgan Stanley | Terence Flynn | Equal-Weight | Maintains | $163.00 |
| Jan 23, 2025 | Leerink Partners | David Risinger | Outperform | Maintains | $169.00 |
| Jan 17, 2025 | B of A Securities | Tim Anderson | Neutral | Maintains | $160.00 |
| Dec 11, 2024 | Citigroup | Joanne Wuensch | Buy | Maintains | $175.00 |
| Dec 10, 2024 | B of A Securities | Tim Anderson | Neutral | Reinstates | $166.00 |
| Nov 15, 2024 | Wolfe Research | Alexandria Hammond | Outperform | Initiates | $190.00 |
| Nov 6, 2024 | Guggenheim | Vamil Divan | Neutral | Maintains | $162.00 |
| Oct 16, 2024 | Citigroup | Joanne Wuensch | Buy | Maintains | $185.00 |
| Oct 16, 2024 | Morgan Stanley | Terence Flynn | Equal-Weight | Maintains | $175.00 |
Johnson & Johnson (JNJ) Competitors
The following stocks are similar to J&J based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Johnson & Johnson (JNJ) Financial Data
Johnson & Johnson has a market capitalization of $392.35B with a P/E ratio of 28.1x. The company generates $88.82B in trailing twelve-month revenue with a 15.8% profit margin.
Revenue growth is +5.3% quarter-over-quarter, while maintaining an operating margin of +18.2% and return on equity of +20.1%.
Valuation Metrics
Growth & Margins
Financial Health
🔥 Want More High-Potential Stock Ideas?
Join 5,000+ investors getting our research on stocks with massive upside potential.
Johnson & Johnson (JNJ) Business Model
About Johnson & Johnson
Multinational corporation in healthcare products.
The company operates by developing and selling a diverse range of healthcare products, including pharmaceuticals, medical devices, and consumer health products. It generates revenue through its extensive portfolio of medications, which address various health conditions, and well-known consumer brands that cater to everyday health needs.
Johnson & Johnson has a strong global presence and is recognized for its commitment to healthcare innovation. Its reputable brands, such as Band-Aid and Tylenol, contribute significantly to its market position, while its research efforts in fields like immunology and oncology ensure it stays relevant in addressing global health challenges.
Company Information
Sector
Healthcare
Industry
Drug Manufacturers - General
Employees
138,100
CEO
Mr. Joaquin Duato
Country
United States
IPO Year
1970
Website
www.jnj.comJohnson & Johnson (JNJ) Latest News & Analysis
Johnson & Johnson (JNJ) is being evaluated for its potential as a strong dividend stock, appealing to investors seeking dividend benefits.
Johnson & Johnson's potential as a dividend stock affects its attractiveness for income-focused investors, influencing stock demand and valuation.
Johnson & Johnson executives will testify in a trial beginning Monday, related to a lawsuit from ChemImage over a failed partnership from 2019.
The trial outcome could impact Johnson & Johnson's financials and reputation, influencing stock performance and investor sentiment.
Cramer's Mad Dash: Johnson & Johnson
5 days agoJim Cramer highlights his interest in Johnson & Johnson shares, indicating potential investment relevance.
Cramer's focus on Johnson & Johnson indicates potential market interest and volatility, influencing investor sentiment and stock performance in the healthcare sector.
Johnson & Johnson announced positive Phase 2b results for icotrokinra, showing up to 30.2% clinical remission in ulcerative colitis patients, with improved rates through Week 28 and a favorable safety profile.
Positive results from the icotrokinra study indicate potential for a new treatment in ulcerative colitis, potentially boosting Johnson & Johnson's market position and revenue prospects.
Johnson & Johnson (JNJ) has garnered significant attention from Zacks.com users, indicating potential interest in the stock's future performance.
Increased interest in Johnson & Johnson suggests potential stock volatility, making it crucial for investors to analyze underlying factors influencing its performance.
Dean Omar Branham Shirley, LLP partners Jessica Dean, Amin Omar, Trey Branham, Lisa Shirley, Ben Braly, and attorney Mark Linder were named among Lawdragon's 500 Leading Plaintiff Consumer Lawyers for 2025.
Recognition of top lawyers enhances the firm's reputation, potentially attracting more clients and increasing revenue, which could positively impact its financial performance and stock value.
Frequently Asked Questions About JNJ Stock
What is Johnson & Johnson's (JNJ) stock forecast for 2025?
Based on our analysis of 28 Wall Street analysts, Johnson & Johnson (JNJ) has a median price target of $166.37. The highest price target is $190.00 and the lowest is $150.00.
Is JNJ stock a good investment in 2025?
According to current analyst ratings, JNJ has 9 Buy ratings, 13 Hold ratings, and 0 Sell ratings. The stock is currently trading at $162.81. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for JNJ stock?
Wall Street analysts predict JNJ stock could reach $166.37 in the next 12 months. This represents a 2.2% increase from the current price of $162.81. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Johnson & Johnson's business model?
The company operates by developing and selling a diverse range of healthcare products, including pharmaceuticals, medical devices, and consumer health products. It generates revenue through its extensive portfolio of medications, which address various health conditions, and well-known consumer brands that cater to everyday health needs.
What is the highest forecasted price for JNJ Johnson & Johnson?
The highest price target for JNJ is $190.00 from Alexandria Hammond at Wolfe Research, which represents a 16.7% increase from the current price of $162.81.
What is the lowest forecasted price for JNJ Johnson & Johnson?
The lowest price target for JNJ is $150.00 from Narumi Nakagiri at Daiwa Capital, which represents a -7.9% decrease from the current price of $162.81.
What is the overall JNJ consensus from analysts for Johnson & Johnson?
The overall analyst consensus for JNJ is neutral. Out of 28 Wall Street analysts, 9 rate it as Buy, 13 as Hold, and 0 as Sell, with a median price target of $166.37.
How accurate are JNJ stock price projections?
Stock price projections, including those for Johnson & Johnson, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
